The company manufactures 30 Large Volume Generic APIs and offers Custom Synthesis of APIs and Intermediates for global companies with a portfolio of products across diverse therapeutic areas. Geographically, the company derives maximum revenue from Europe, and the rest from America, India, Asia (excluding India), and the Rest of the world. Divis Laboratories' strong performance in custom synthesis business demonstrates the company's resilience and strategic positioning in the pharmaceutical industry, while continuing to invest in future growth opportunities, particularly in custom synthesis and peptide development.
Cyborg Score Rationale
Divis demonstrates strong market positioning with a market capitalization of $18.9B and trailing twelve-month revenue of $1.16B. Custom synthesis segment showing robust growth with expanding opportunities in peptides. However, company faces headwinds from export challenges and pricing pressures in generic APIs segment.
Top Insights
Custom synthesis business is driving growth amid ongoing pricing pressures in the generics segment
Company manufactures 30 Large Volume Generic APIs and exports them to 100+ countries
Monthly exports have fallen by 59.00%, while yearly exports have declined by 38.00%, indicating challenges in international business operations
700+ scientists across three R&D centers develop commercially viable processes for custom synthesis projects
Named Competitors
Syngene International — Contract research and manufacturing services
Laurus Labs — API and specialty pharmaceutical manufacturer
Zydus Lifesciences — Integrated pharmaceutical company
Granules India — Formulation and API manufacturer
Recent Developments
(December 2025) Q3 FY26 consolidated income Rs2,692cr; PBT Rs780cr with earnings call held on February 11, 2026
(November 2025) 17% revenue growth in Q2 FY2026 reported with custom synthesis business driving performance
(August 2025) Reports mixed Q1 results with 15% revenue growth driven by custom synthesis expansion
(May 2025) Q4 results show EBITDA surge of 21% and net profit jump of 23%
Open the full interactive Divi's Laboratories Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.